DOCSLIB.ORG

Beta-Cyclodextrin-Drospirenone Inclusion Complexes Einschlusskomplexe Von Drospirenone Und Beta-Cyclodextrin Complexes D’Inclusion Béta-Cyclodextrine-Drospirenone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beta-Cyclodextrin-Drospirenone Inclusion Complexes Einschlusskomplexe Von Drospirenone Und Beta-Cyclodextrin Complexes D’Inclusion Béta-Cyclodextrine-Drospirenone (19) & (11) EP 1 353 699 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 47/48 (2006.01) A61K 31/585 (2006.01) 01.02.2012 Bulletin 2012/05 B82Y 5/00 (2011.01) A61P 15/18 (2006.01) A61P 15/12 (2006.01) (21) Application number: 01271230.3 (86) International application number: (22) Date of filing: 20.12.2001 PCT/IB2001/002604 (87) International publication number: WO 2002/049674 (27.06.2002 Gazette 2002/26) (54) Beta-cyclodextrin-drospirenone inclusion complexes Einschlusskomplexe von Drospirenone und Beta-Cyclodextrin Complexes d’inclusion béta-cyclodextrine-drospirenone (84) Designated Contracting States: • KRATTENMACHER ROLF: "Drospirenone: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Pharmacology and pharmacokinetics of a unique MC NL PT SE TR progestogen." CONTRACEPTION, vol. 62, no. 1, Designated Extension States: July 2000 (2000-07), pages 29-38, XP000993492 LT LV RO SI ISSN: 0010-7824 • NORMAN P ET AL: "Drospirenone: (30) Priority: 20.12.2000 EP 00610134 Contraceptive, hormone replacement therapy, 20.12.2000 US 256483 P aldosterone antagonist, progestogen: 1,2- dihydrospirorenone, SH-470, ZK-30595." DRUGS (43) Date of publication of application: OF THE FUTURE, vol. 25, no. 12, December 2000 22.10.2003 Bulletin 2003/43 (2000-12), pages 1247-1256, XP000993474 ISSN: 0377-8282 (73) Proprietor: Bayer Pharma Aktiengesellschaft • UEKAMA, K. ET AL: "Inclusion complexations of 13353 Berlin (DE) steroid hormoneswith cyclodextrins inwater and in solid phase" INT. J. PHARM., 1982, VOL. 10, (72) Inventors: NO. 1, PAGES 1-15, XP000610489 • BACKENSFELD, Thomas • KRALOVA, K. ET AL: "Interactions of beta 13127 Berlin (DE) -cyclodextrin with steroid compounds in • HEIL, Wolfgang aqueous solutions" PHARMAZIE, 1989, VOL. 44, 21435 Stelle (DE) NO. 9, PAGES 623-5, XP000611476 • HERMENS W.A.J.J.: "Delivery of hormones: (74) Representative: Plougmann & Vingtoft A/S Somenew concepts" PHARM. WEEKBL. SCI. ED., Sundkrogsgade 9 1992, VOL. 14, NO. 4 A, PAGE(S) 253-257, P.O. Box 831 XP002167344 NETHERLANDS 2100 Copenhagen Ø (DK) • K. UEKAMA: "CYCLODEXTRIN INCLUSION COMPOUNDS: EFFECTS ON STABILITY AND (56) References cited: BIO-PHARMACEUTICAL PROPERTIES" TOPICS EP-A- 0 398 460 WO-A-96/02277 IN PHARMACEUTICAL SCIENCES, EDS. D.D. WO-A1-01/15701 FR-A- 2 515 187 BREIMER AND P. SPEISER, 1987, ELSEVIER GB-A- 2 109 381 SCIENCE PUBLISHERS B.V. (BIOMEDICAL DIVISION), PAGES 181-194, XP002167345 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 353 699 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 1 353 699 B1 • UEKAMA K ET AL: "CYCLODEXTRIN DRUG • MELIA C D ET AL: "Review article: Mechanisms CARRIER SYSTEMS" CHEMICAL REVIEWS,US, of drug release from tablets and capsules. 2. AMERICAN CHEMICAL SOCIETY. EASTON, vol. Dissolution", ALIMENTARY PHARMACOLOGY 98, no. 5, 1 July 1998 (1998-07-01), pages AND THERAPEUTICS, vol. 3, no. 6, 1989, pages 2045-2076, XP000771829 ISSN: 0009-2665 513-525, ISSN: 0269-2813 • DALLA BELLA M ET AL: "CYCLODEXTRINS", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, Remarks: vol. 8, no. 5, 1 January 1983 (1983-01-01) , pages Thefile contains technical information submitted after 391-394, XP008020709, ISSN: 0377-8282 the application was filed and not included in this specification 2 EP 1 353 699 B1 Description FIELD OF INVENTION 5 [0001] The present invention relates to an inclusion complex formed betweenβ -cyclodextrin and drospirenone and to methods of providing such an inclusion complex. Moreover, the present invention relates to the use of said inclusion complex in pharmaceutical compositions for use as a medicament in the treatment of symptoms associated with men- opause and in female contraception. 10 BACKGROUND OF THE INVENTION [0002] Drospirenone (6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone), which may be pre- pared substantially as described in e.g. US 4,129,564 or WO 98/06738, is only sparingly soluble in aqueous media at various pH values. 15 [0003] The water solubility of a compound is extremely pertinent with regards to its utility In industry, particularly in the pharmaceutical industry where there is a strong link between water solubility and bioavailability. The therapeutic efficiency of drospirenone may be improved by increasing its overall water solubility, thus providing for routes of admin- istration alternative to those proceeding via the gastrointestinal tract, where absorption is slow and then rapidly cleared from circulating blood by the liver. 20 [0004] Cyclodextrins are known to solubilize nonpolar compounds and improve the absorption of certain compounds by forming complexes with said compounds. The cyclodextrins are frequently derivatized in order to improve the solubility or to accommodate appropriately the compound of interest. However, certain compounds are not well accommodated by the cavity of the some of the cyclodextrin molecules. [0005] Drospirenone, in its uncomplexed form, is known from DE 26 52 761 in which its use as a diuretic compound 25 is disclosed. [0006] EP 0 398 460 described the use of drospirenone for contraception and for symptoms associated with meno- pause. [0007] U5 4,596,795 discloses a complex between α-, p- and γ-cyclodextrins and derivatives thereof with testosterone, progesterone, and estradiol and the solubility of said complexes. 30 [0008] US 5,885,978 relates to a composition comprising an adrenal cortical steroid and cyclodextrin prepared by clathrating the adrenal cortical steroid in the cyclodextrin using a homomixer. [0009] US 5,376,641 discloses a method of making a steroid water soluble by mixing a steroid and a branched beta cyclodextrin together in water for a period of 4 to 24 hours under ambient conditions. [0010] US 5,376,641 discloses a method for making a steroid water soluble by complexing the steroid with branched 35 β-cyclodextrin. [0011] US 4,727,064 discloses a method of improving the dissolution properties of.a steroid by forming a solid com- prising at least one of testosterone, progesterone and estradiol as an inclusion complex with a poly-β-cyclodextrin and /or hydroxypropyl-β-cyclodextrin adapted for administration by buccal route. [0012] FR 2 515 187 discloses inclusion complexes between γ-cyclodextrines and various steroids, such as a spironol- 40 actone steroid. [0013] WO 96/02277 discloses pharmaceutical compositions containing cyclodextrin-clathrate complexes of steroid sexual hormones for protection against oxidative degradation of steroids. SUMMARY OF THE INVENTION 45 [0014] The invention relates to an inclusion complex between β-cyclodextrin and 6β,7β; 15β,16β-dimethylene-3-oxo- 17α-pregn-4-ene-21,17-carbolactone (drospirenone) where the molar ratio between drospirenone and the β-cyclodextrin is 1:3. [0015] The invention also relates to a method for producing the inclusion complex according to the invention. 50 [0016] One object of the present invention is to increase the water-solubility of drospirenone. The present invention thus further discloses methods for improving the solubility of drospirenone, said method comprising forming an inclusion complex between drospirenone and β-cyclodextrin. [0017] In a further aspect of the invention, pharmaceutical compositions comprising an inclusion complex of dros- pirenone and β-cyclodextrin are described. Consequently, the inclusion complex between drospirenone andβ -cyclo- 55 dextrin for use for female contraception or for the treatment of menopausal symptoms are defined herein. 3 EP 1 353 699 B1 DETAILED DESCIPTION OF THE INVENTION [0018] The term "inclusion complex" is intended to mean a complex wherein at least a moiety of drospirenone has inserted itself, at least partially, into the cavity of cyclodextrin. 5 [0019] In efforts to improve the functional utility of drospirenone, research has led- to a new chemical entity, an inclusion complex between β- cyclodextrin and drospirenone in a motar ratio of 3:1. [0020] The β-cyclodextrin may be modified such that some or all of the primary or secondary hydroxyls of the macrocyle, or both, may be alkylated or acylated. Methods of modifying these alcohols are well known to the person skilled in the art and many derivatives are commercially available. The β-cyclodextrin may be modified such that one or more of the 10 primary or secondary hydroxyls of the macrocyle, or both, may be alkylated or acylated. Methods of modifying these alcohols are well known to the person skilled in the art and many are commercially available. Thus, some or all of the hydroxyls of β-cyclodextrin may have be substituted with an O-R group or an O-C(O)-R, wherein R is an optionally substitutedC 1-6 alkyl, an optionally substituted C 2-6alkenyl, anoptionally substituted C 2-6 alkynyl,an optionally substituted aryl or heteroaryl group. R may be methyl, ethyl, propyl, butyl, pentyl, or hexyl group. Consequently, O-C (O)-R may be 15 an acetate. Furthermore, R may be such as to derivatizeβ -cyclodextrin with the commonly employed 2-hydroxyethyl group, or 2-hydroxypropyl group. Moreover, the β-cyclodextrin alcohols may be perbenzylated, per-benzoylated, or benzylated or benzoylated on just one face of the macrocycle, or wherein only 1, 2, 3, 4, 5, or 6 hydroxyls are benzylated or benzoylated. The hydroxyl groups of β-cyclodextrin may be per-alkylated or per-acylated such as permethylated or per-acetylated, or alkylated or acylated, such as methylated or acetylated, on just one face of the macrocycle, or wherein 20 only 1, 2, 3, 4, 5, or 6 hydroxyls are alkylated or acylated, such as methylated or acetylated.
Load more

Recommended publications
  • 232383538.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Groningen University of Groningen X-ray Structure of Cyclodextrin Glycosyltransferase Complexed with Acarbose. Implications for the Catalytic Mechanism of Glycosidases STROKOPYTOV, B; PENNINGA, D; ROZEBOOM, HJ; KALK, KH; DIJKHUIZEN, L; DIJKSTRA, BW Published in: Biochemistry DOI: 10.1021/bi00007a018 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1995 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): STROKOPYTOV, B., PENNINGA, D., ROZEBOOM, HJ., KALK, KH., DIJKHUIZEN, L., & DIJKSTRA, BW. (1995). X-ray Structure of Cyclodextrin Glycosyltransferase Complexed with Acarbose. Implications for the Catalytic Mechanism of Glycosidases. Biochemistry, 34(7), 2234-2240. https://doi.org/10.1021/bi00007a018 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
    [Show full text]
  • Cyclodextrin Enhanced the Soluble Expression of Bacillus Clarkii Γ-Cgtase in Escherichia Coli Lei Wang1,2, Sheng Chen1,2 and Jing Wu1,2*
    Wang et al. BMC Biotechnology (2018) 18:72 https://doi.org/10.1186/s12896-018-0480-8 RESEARCHARTICLE Open Access Cyclodextrin enhanced the soluble expression of Bacillus clarkii γ-CGTase in Escherichia coli Lei Wang1,2, Sheng Chen1,2 and Jing Wu1,2* Abstract Background: Cyclodextrin glycosyltransferases (CGTases) catalyze the synthesis of cyclodextrins, which are circular α-(1,4)-linked glucans used in many applications in the industries related to food, pharmaceuticals, cosmetics, chemicals, and agriculture, among others. Economic use of these CGTases, particularly γ-CGTase, requires their efficient production. In this study, the effects of chemical chaperones, temperature and inducers on cell growth and the production of soluble γ-CGTase by Escherichia coli were investigated. Results: The yield of soluble γ-CGTase in shake-flask culture approximately doubled when β-cyclodextrin was added to the culture medium as a chemical chaperone. When a modified two-stage feeding strategy incorporating 7.5 mM β-cyclodextrin was used in a 3-L fermenter, a dry cell weight of 70.3 g·L− 1 was achieved. Using this cultivation approach, the total yield of γ-CGTase activity (50.29 U·mL− 1) was 1.71-fold greater than that observed in the absence of β-cyclodextrin (29.33 U·mL− 1). Conclusions: Since β-cyclodextrin is inexpensive and nontoxic to microbes, these results suggest its universal application during recombinant protein production. The higher expression of soluble γ-CGTase in a semi-synthetic medium showed the potential of the proposed process for the economical production of many enzymes on an industrial scale. Keywords: Cyclodextrin glycosyltransferase, Cyclodextrin, Chemical chaperones, Overexpression, Escherichia coli Background biodegradation [3]; thus, γ-cyclodextrin has found much Cyclodextrin glycosyltransferases (EC 2.4.1.19, CGTase) wider application in industrial settings.
    [Show full text]
  • Effects of Progesterone and Testosterone on Cocaine Self-Administration and Cocaine Discrimination by Female Rhesus Monkeys
    Neuropsychopharmacology (2011) 36, 2187–2199 & 2011 American College of Neuropsychopharmacology. All rights reserved 0893-133X/11 www.neuropsychopharmacology.org Effects of Progesterone and Testosterone on Cocaine Self-Administration and Cocaine Discrimination by Female Rhesus Monkeys Nancy K Mello*,1, Inge M Knudson1, Maureen Kelly1, Peter A Fivel1 and Jack H Mendelson1 1 Alcohol and Drug Abuse Research Center, McLean HospitalFHarvard Medical School, Belmont, MA, USA The neuroactive steroid hormone progesterone attenuates cocaine’s abuse-related effects in women and in rodents under some conditions, but the effects of testosterone are unknown. We compared the acute effects of progesterone (0.1, 0.2, and 0.3 mg/kg, intramuscularly (i.m.)), testosterone (0.001, 0.003, and 0.01 mg/kg, i.m.), and placebo on cocaine self-administration and cocaine discrimination dose–effect curves in female rhesus monkeys. Cocaine self-administration (0.03 mg/kg per inj.) was maintained on a fixed ratio 30 schedule of reinforcement, and monkeys had unlimited access to cocaine for 2 h each day. Cocaine doses were administered in an irregular order during each dose–effect curve determination, and the same dose order was used in each subject in all treatment conditions. Blood samples for hormone analysis were collected at the end of each test session. Banana-flavored food pellets (1 g) were also available in three 1-h daily sessions. In drug discrimination studies, the effects of pretreatment with progesterone (0.032–0.32 mg/kg, i.m.) and testosterone (0.001–0.01 mg/kg, i.m.) on the discriminative stimulus effects of cocaine (0.18 mg/kg, i.m.) were examined.
    [Show full text]
  • Cyclodextrin-Enabled Insulin Delivery
    VOLUME 32. No 2. VOLUME 32. No. 3. MARCH 2018 ISSN 0951-256X Cyclodextrin-enabled Insulin Delivery Introduction Insulin is a peptide hormone produced by beta cells in pancreatic islets. Its main task is the regulation of the metabolism of carbohydrates, fats and protein. In diabetes the insulin production is not enough to keep the blood sugar levels within normal bounds, therefore external insulin should be supplied. The human insulin is composed of 51 amino acids and 3 disulfide bonds; it has a molecular mass of 5808 Da and low aqueous solubility. Bovine insulin differs from human in only 3 amino acids and porcine insulin in one. Insulin is produced and stored in the body as a hexamer (Fig. 1), while the active form is the monomer. The hexamer is much more stable than the monomer. Fig. 1 The structure of insulin hexamer (the magenta sphere is zinc ion, wikipedia) Human insulin is manufactured by recombinant DNA technology, but some patients observing adverse effects to synthetic insulin use animal-source insulin. The oral administration of peptides and proteins is of low efficiency because of the enzymatic degradation in the gastrointestinal tract and poor transport characteristics. That is the reason why insulin is administered via parenteral injections. Edited and produced by: CYCLOLAB – page 1 VOLUME 32. No 2. While developing the devices used for insulin injections (to reduce the pain and local irritation as well as the frequency of application), researchers have been taking continuous efforts on finding novel non-invasive formulations. • One of the aims is protection of insulin from proteolysis in the digestive tract so that it can be administered orally or sublingually.
    [Show full text]
  • Cyclodextrin-Catalyzed Organic Synthesis: Reactions, Mechanisms, and Applications
    molecules Review Cyclodextrin-Catalyzed Organic Synthesis: Reactions, Mechanisms, and Applications Chang Cai Bai 1,† ID , Bing Ren Tian 1,†, Tian Zhao 1, Qing Huang 1,2,* and Zhi Zhong Wang 1,2,* 1 School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; [email protected] (C.C.B.); [email protected] (B.R.T.); [email protected] (T.Z.) 2 Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Yinchuan 750004, China * Correspondence: [email protected] (Q.H.); [email protected] (Z.Z.W.); Tel.: +86-0951-688-0582 (Z.Z.W.) † These authors contributed equally to this work. Received: 2 August 2017; Accepted: 2 September 2017; Published: 7 September 2017 Abstract: Cyclodextrins are well-known macrocyclic oligosaccharides that consist of α-(1,4) linked glucose units and have been widely used as artificial enzymes, chiral separators, chemical sensors, and drug excipients, owing to their hydrophobic and chiral interiors. Due to their remarkable inclusion capabilities with small organic molecules, more recent interests focus on organic reactions catalyzed by cyclodextrins. This contribution outlines the current progress in cyclodextrin-catalyzed organic reactions. Particular emphases are given to the organic reaction mechanisms and their applications. In the end, the future directions of research in this field are proposed. Keywords: cyclodextrin; catalysis; mechanism; green chemistry; organic reaction; asymmetric reaction 1. Introduction Supramolecular chemistry is defined as the chemistry of the intermolecular bond, and focuses on the chemical systems made up of a discrete number of assembled molecular subunits or components. It aims at developing highly complex chemical systems from molecular components reversibly held together by non-covalent intermolecular forces [1,2].
    [Show full text]
  • RR-17: Scoping Review of Prenatal
    NTP RESEARCH REPOrt ON THE SCOPING REVIEW OF PRENATAL EXPOSURE TO PROGESTOGENS AND ADVERSE HEALTH OUTCOMES NTP RR 17 SEPTEMBER 2020 NTP Research Report on the Scoping Review of Prenatal Exposure to Progestogens and Adverse Health Outcomes Research Report 17 September 2020 National Toxicology Program Public Health Service U.S. Department of Health and Human Services ISSN: 2473-4756 Research Triangle Park, North Carolina, USA Scoping Review of Prenatal Exposure to Progestogens and Adverse Health Outcomes Foreword The National Toxicology Program (NTP), established in 1978, is an interagency program within the Public Health Service of the U.S. Department of Health and Human Services. Its activities are executed through a partnership of the National Institute for Occupational Safety and Health (part of the Centers for Disease Control and Prevention), the Food and Drug Administration (primarily at the National Center for Toxicological Research), and the National Institute of Environmental Health Sciences (part of the National Institutes of Health), where the program is administratively located. NTP offers a unique venue for the testing, research, and analysis of agents of concern to identify toxic and biological effects, provide information that strengthens the science base, and inform decisions by health regulatory and research agencies to safeguard public health. NTP also works to develop and apply new and improved methods and approaches that advance toxicology and better assess health effects from environmental exposures. NTP reports the findings from many of its studies in the NTP Technical Report and Monograph series. NTP uses the Research Report series, which began in 2016, to report on work that does not fit readily into one of those two series, such as pilot studies, assay development or optimization studies, literature surveys or scoping reviews, and handbooks on NTP procedures or study specifications.
    [Show full text]
  • Download (Accessed on 6 November 2020)
    biomolecules Review Cyclodextrins, Natural Compounds, and Plant Bioactives—A Nutritional Perspective Svenja Wüpper *, Kai Lüersen and Gerald Rimbach Institute of Human Nutrition and Food Science, University of Kiel, Hermann-Rodewald-Strasse 6, 24118 Kiel, Germany; [email protected] (K.L.); [email protected] (G.R.) * Correspondence: [email protected]; Tel.: +49-431-880-5334 Abstract: Cyclodextrins (CDs) are a group of cyclic oligosaccharides produced from starch or starch derivatives. They contain six (αCD), seven (βCD), eight (γCD), or more glucopyranose monomers linked via α-1,4-glycosidic bonds. CDs have a truncated cone shape with a hydrophilic outer wall and a less hydrophilic inner wall, the latter forming a more apolar internal cavity. Because of this special architecture, CDs are soluble in water and can simultaneously host lipophilic guest molecules. The major advantage of inclusion into CDs is increased aqueous solubility of such lipophilic substances. Accordingly, we present studies where the complexation of natural compounds such as propolis and dietary plant bioactives (e.g., tocotrienol, pentacyclic triterpenoids, curcumin) with γCD resulted in improved stability, bioavailability, and bioactivity in various laboratory model organisms and in humans. We also address safety aspects that may arise from increased bioavailability of plant extracts or natural compounds owing to CD complexation. When orally administered, α- and βCD—which are inert to intestinal digestion—are fermented by the human intestinal flora, while γCD is almost completely degraded to glucose units by α-amylase. Hence, recent reports indicate that empty γ CD supplementation exhibits metabolic activity on its own, which may provide opportunities for new applications.
    [Show full text]
  • Article J Incl Phenom Macrocycl Chem 2007
    J Incl Phenom Macrocycl Chem (2007) 57:283–288 DOI 10.1007/s10847-006-9174-2 ORIGINAL ARTICLE Water soluble progesterone–hydroxypropyl-b-cyclodextrin complex for injectable formulations G. Zoppetti Æ N. Puppini Æ M. Pizzutti Æ A. Fini Æ T. Giovani Æ S. Comini Received: 15 May 2006 / Accepted: 20 October 2006 / Published online: 28 February 2007 Ó Springer Science+Business Media B.V. 2007 Abstract The use of cyclodextrin to increase the have developed a production process in which the water solubility of progesterone (P) was described by residual unreacted b-cyclodextrin is separated from Pitha as a complex with b-cyclodextrin and derivates the HPBCD by the formation of the insoluble inclu- to obtain a water soluble formulation (Pitha, J.: US sion complex (Zoppetti et al.: European Patent de- patent n. 4,727,064). Hydroxypropyl-b-cyclodextrin posit n. 05108494.5). The resulting P/HPBCD contains (HPBCD) has a high water solubility which allows the up to 0.1% of residual b-cyclodextrin and does not solubilization of high quantity of P. Considering a 1:2 produce precipitate during the stability study. The guess/host complex stoichiometry it is possible to complex stoichiometry and the complex constant were obtain up to 50 mg/ml of P concentration, which is a calculated by the phase solubility study according to considerable dosage for drug development in the Higuchi and Connors (Adv. Anal. Chem. Instrum. 4, progesterone therapy. In our drug development the P/ 117, 1965) and the presence of the inclusion complex HPBCD complex in water showed the formation of a was demonstrated by DSC, NMR, X-ray, FTIR.
    [Show full text]
  • (Jordanella Floridae) Over One Complete Life-Cycle
    The Effects of Hydroxypropyl-β-Cyclodextrin on the American Flagfish (Jordanella floridae) Over One Complete Life-Cycle by Jordan Christopher Anderson A Thesis Submitted in Partial Fulfillment of the Requirements of the Degree of Masters of Science in The Faculty of Science Applied Bioscience University of Ontario Institute of Technology August, 2013 © Jordan Christopher Anderson, 2013 Abstract Understanding the impacts of pharmaceuticals and personal care products (PPCPs) on aquatic ecosystems is an important issue in aquatic toxicology. Many PPCPs have been shown to cause effects on aquatic biota within detected environmental ranges. One compound of particular interest is hydroxylpropyl-β-cyclodextrin (HPβCD), the active ingredient in Febreeze®, and widely used for many applications. HPβCD is amphiphilic, toroidal in shape, and able to form non-covalent inclusion complexes with a variety of guest molecules. HPβCD has been shown to reduce volatility as well as improve the aqueous solubility of apolar guest compounds. As such, the use of HPβCD in the pharmaceutical and personal care industry has dramatically increased. With increasing potential for entering the environment through wastewater treatment plant (WWTP) effluent, HPβCD poses an unknown risk to non-target aquatic biota. As a result, a 145-day chronic full life-cycle exposure using American flagfish (Jordanella floridae) was completed using flow-through concentrations of 0 (control), 5, 16, 50,160, 500, and 1600 µg/L of HPβCD maintained via a peristaltic pump. No significant differences were observed in growth, condition factor (K) and hepatosomatic index (HSI) when chronically exposed to HPβCD (P ≤ 0.05). A significant increase in female gonadosomatic index (GSI) occurred in those exposed to HPβCD (P ≤ 0.05).
    [Show full text]
  • Supramolecular Hydrogels of Β-Cyclodextrin Linked to Calcium Homopoly-L- Guluronate for Release of Coumarins with Trypanocidal Activity T ⁎ M
    Carbohydrate Polymers 204 (2019) 170–181 Contents lists available at ScienceDirect Carbohydrate Polymers journal homepage: www.elsevier.com/locate/carbpol Supramolecular hydrogels of β-cyclodextrin linked to calcium homopoly-L- guluronate for release of coumarins with trypanocidal activity T ⁎ M. Moncada-Basualtoa,b, , B. Matsuhiroa, A. Mansillac,d, M. Lapiere, J.D. Mayae, C. Olea-Azarb a Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Av. L. B. O’Higgins 3363, Santiago, Chile b Departamento de Química Inorgánica y Analítica, Facultad de Ciencias Química y Farmacéuticas, Universidad de Chile, Av. Sergio Livingstone 1007, Santiago, Chile c Laboratorio de Macroalgas Antárticas y Subantárticas, Universidad de Magallanes, Av. Bulnes 1465, Punta Arenas, Chile d Instituto de Ecología y Biodiversidad, Chile e Departamento de Farmacología Molecular y Clínica, Facultad de Medicina, Universidad de Chile, Av. Independencia 1107, Santiago, Chile ARTICLE INFO ABSTRACT Keywords: Association constants and thermodynamicsparameters on inclusion of four 3-amido coumarins that present Homopoly-L-guluronate trypanocidal activity, into 6-amino-β-cyclodextrin (1:1 stoichimetry) were determined. In addition, pure 3-Amidocoumarins homopolymeric-α-L-guluronate fraction prepared by partial hydrolysis of sodium alginate from Sub-Antarctic Inclusion complex Kelp Durvillaea antarctica was conjugated with 6-amino-β-cyclodextrin (64% yield). To glycoconjugates, 3-amido Trypanosoma cruzi coumarins were incorporated (73% of encapsulation) and supramolecular hydrogels were prepared by gelation Supramolecular hydrogel with Ca2+ ions. Sub-Antarctic macroalgae The trypanocidal activity of the inclusion complexes increased by 10%. Likewise, an increase in diffusion in artificial membrane was observed (13%). It was found that the inclusion complexes increased the variation of the mitochondrial potential of T.
    [Show full text]
  • Alpha-Cyclodextrin Attenuates the Glycemic and Insulinemic Impact of White Bread in Healthy Male Volunteers
    foods Article Alpha-Cyclodextrin Attenuates the Glycemic and Insulinemic Impact of White Bread in Healthy Male Volunteers Albert Bär 1,* , Ioannis Diamantis 2 and Werner P. Venetz 3 1 Bioresco Ltd., 4054 Basel, Switzerland 2 Gastro Center, 2502 Biel, Switzerland; [email protected] 3 Datagen AG, 3930 Visp, Switzerland; [email protected] * Correspondence: [email protected] Received: 28 November 2019; Accepted: 3 January 2020; Published: 7 January 2020 Abstract: The demonstration of a physiological benefit has recently become an indispensible element of the definition of dietary fibers. In the here-reported pilot study, the effect of alpha-cyclodextrin (alpha-CD) on the postprandial glycemic and insulinemic effect of starch was examined. Twelve fasted, healthy male volunteers received, on three subsequent days, a test breakfast consisting of (A) 100 g fresh white bread (providing 50 g starch) and 250 mL drinking water, (B) the same bread with a supplement of 10 g alpha-CD dissolved in the drinking water, and (C) 25 g alpha-CD dissolved in drinking water. Capillary and venous blood was sampled before the breakfast and in regular intervals for a three-hour period thereafter. Glucose was determined in capillary blood and insulin in the plasma of venous blood samples. Breakfast (A) led to a rapid rise in blood glucose and insulin. In breakfast (B), alpha-CD reduced the areas under the curve of blood glucose and insulin significantly by 59% and 57%, respectively, demonstrating that alpha-CD inhibits and thereby delays starch digestion. Treatment (C) was not associated with a rise of blood glucose. Hence, alpha-CD complies with the current definition of dietary fiber in every respect.
    [Show full text]
  • Background Review for Cyclodextrins Used As Excipients
    20 November 2014 EMA/CHMP/333892/2013 Committee for Human Medicinal Products (CHMP) Background review for cyclodextrins used as excipients In the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ (CPMP/463/00 Rev. 1) Draft report published in support to the propylene glycol Q&A document. For information only 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents Executive summary ..................................................................................... 3 Introduction ................................................................................................ 3 1. Characteristics......................................................................................... 3 2. Kinetic/toxicological data and clinical safety .......................................... 4 2.1. Oral products ....................................................................................................... 4 2.2. Nasal and pulmonary products ............................................................................... 5 2.3. Rectal products .................................................................................................... 6 2.4. Dermal products .................................................................................................
    [Show full text]